Does Myocardial Extracellular Volume Fraction (ECV) improve prognostic assessment for heart failure outcomes beyond Late Gadolinium Enhancement (LGE)?
Myocardial Extracellular Volume Fraction (ECV) provides prognostic value for heart failure outcomes independent of and synergistic with replacement fibrosis (LGE).
ECV measures of diffuse myocardial fibrosis were associated with HF outcomes, despite exclusion of replacement fibrosis segments from their derivation and even among patients without any scar. ECV may have a synergistic role with LGE in HF risk assessment.
Yang et al. (Sun,) studied this question.